Acute IRAK-4 Variants in acute coronary syndrome patients

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Ticagrelor-associated thrombotic thrombocytopenic purpura

  2017cited by this paper
• 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2016cited by this paper
• Increased PTPN22 expression and defective CREB activation impair regulatory T-cell differentiation in non-ST-segment elevation acute coronary syndromes.

  2015cited by this paper
• Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents.

  2014cited by this paper
• The immune system in atherosclerosis

  2011cited by this paper
• Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes.

  2010cited by this paper
• Genetic ablation of IRAK4 kinase activity inhibits vascular lesion formation.

  2008cited by this paper
• The interleukin‐1 receptor/Toll‐like receptor superfamily: 10 years of progress

  2008cited by this paper
• Use of ticlopidine and cilostazol after intracoronary drug-eluting stent placement in a patient with previous clopidogrel-induced thrombotic thrombocytopenic purpura: a case report.

  2006cited by this paper

• No citing papers are available for this paper.